Increased Matrix Metalloproteinase-9 Predicts Poor Wound Healing in Diabetic Foot Ulcers

YU LIU, MD1 DANQING MIN, PHD2 THYRA BOLTON3 VANESSA NUBÉ3 STEPHEN M. TWIGG, PHD, MD1,2,3 DENNIS K. YUE, PHD, MD1,2,3 SUSAN V. MCLENNAN, PHD1,2

OBJECTIVE — We studied the relationships of diabetic ulcer wound fluid matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and transforming growth factor-β1 (TGF-β1) with wound healing rate.

RESEARCH DESIGN AND METHODS — The ulcers were cleansed to remove exudates, and wound fluids were collected for analysis of MMP-2 and -9, TIMP-1, and TGF-β1.

RESULTS — At presentation, MMP-9 and the MMP-9-to–TIMP-1 ratio correlated inversely with the wound healing rate at 28 days (P < 0.001). MMP-9 and the MMP-9-to–TIMP-1 ratio were lower in the 23 patients who achieved complete healing at 12 weeks versus the 39 who did not. The pro–MMP-9 concentration was predictive of healing within 12 weeks. Addition of cutoffs for TIMP-1 (>480 pg/ml) and TGF-β1 (>115 pg/ml) further improved its predictive power (area under the curve 0.94).

CONCLUSIONS — These findings suggest that a milieu with high MMP-9 may be indicative of inflammation and poor wound healing. Measurements of MMP-9, TIMP-1, and TGF-β1 in wound fluid may help to identify ulcers at risk of poor healing.

Diabetes Care 32:117–119, 2009

Diabetic foot ulcers often fail to heal, and the mechanism is not well explained (1). In previous studies of wounds, delayed healing is characterized by an increase in matrix metalloproteinases (MMPs), a decrease in the tissue inhibitors of metalloproteinases (TIMPs), and a reduction in some growth factors, in particular, transforming growth factor-β (TGF-β) (2–9). Both MMPs and TIMPs are secreted by cells involved in wound healing, and their concentrations vary according to the phase of healing (4,6).

Studies of diabetic foot ulcer wounds in humans are limited as a result of the difficulty of obtaining tissue samples. Wound fluid can be obtained noninvasively and could potentially overcome this problem. The clinical relevance of studying wound fluid is supported by our previous report that high bacterial count in diabetic wound fluid has a negative impact on wound healing (10). Therefore, the aim of this study was to measure MMP-9, MMP-2, TIMP-1, and TGF-β1 in wound fluid obtained from diabetic foot ulcers to examine their relationships with wound healing.

RESEARCH DESIGN AND METHODS — Patient characteristics are shown in Table 1. The majority of patients had type 2 diabetes (n = 56), and their ulcers were classified as neuropathic (n = 48), postsurgical (n = 9), or neuroischemic (n = 9) and graded according to the Texas Grading System (11). The ulcers had been present for 2–10 weeks before presentation. All patients were seen weekly for debridement, offloading, and other treatments during the initial 4 weeks and attended approximately monthly visits thereafter. Antibiotics were prescribed for 83% of individuals. The protocol was approved by the ethics committee of the area.

Wound fluids were collected from the ulcer site at the first clinic visit and after 4 weeks of treatment. Samples were stored at −20°C for quantitation of MMP-2 and -9 by zymography (12) and TIMP-1 and TGF-β1 by enzyme-linked immunosorbent assay. Ulcer size and wound healing rates (WHRs) were determined as previously described (10).

Students t test or one-way ANOVA was used for comparisons. Multiple regression analysis was used to determine the relationships between WHR4 weeks, age, duration of diabetes and ulceration, wound fluid pro- and active–MMP-9 and -2, TIMP-1, and TGF-β1. Receiver operating characteristic analysis was used to determine thresholds for pro–MMP-9 in predicting healing within 12 weeks.

RESULTS — At 4 weeks, none of the ulcers had healed, but by 12 weeks, 23 of the 62 ulcers had completely healed. There were no differences in age, duration of diabetes, or initial size of the ulcer between the healed and unhealed groups (Table 1).

Wound fluid pro–MMP-9 and pro–MMP-9-to–TIMP-1 ratio at presentation correlated significantly with WHR4 weeks (r = 0.4538, P < 0.001, and r = 0.4959, P < 0.0001, respectively). This relationship was not evident for MMP-2 or TIMP-1. The concentrations of pro- and active–MMP-9 in the wound fluid obtained at presentation were significantly higher and those of TIMP-1 and TGF-β1 significantly lower in ulcers that subsequently failed to heal than in ulcers that healed within 12 weeks (Table 1). When the data were expressed as pro–MMP-9–to–TIMP-1 and active–MMP-9–to–TIMP-1 ratios, the difference between the healed and unhealed groups was further enhanced. This pattern of higher MMP-9 was evident in both stage B and stage C.

From the 1Discipline of Medicine, University of Sydney, Sydney, Australia; the 2Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, Australia; and the 3Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia.

Corresponding author: Susan McLennan, smclennan@med.usyd.edu.au.

Received 21 April 2008 and accepted 18 September 2008.

Published ahead of print at http://care.diabetesjournals.org on 3 October 2008. DOI: 10.2337/dc08-0763 © 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
MMP-9 predicts poor wound healing

Table 1—Patient and wound fluid characteristics at the initial visit grouped according to subsequent healing status at 12 weeks

|                          | Healed ulcers | Unhealed ulcers |
|--------------------------|---------------|-----------------|
| **Total sample**         |               |                 |
| Patients                 | 23            | 39              |
| Sex (men)                | 17            | 32              |
| Age (years)              | 59 ± 11       | 62 ± 9          |
| Diabetes duration (years)| 14 ± 5        | 16 ± 12         |
| A1C (%)                  | 9.5 ± 1.9     | 7.7 ± 2.1*      |
| Antibiotic treatment     | 20            | 32              |
| After 4 weeks            |               |                 |
| Ulcer size (mm²)         | 91.7 ± 146.7  | 213.4 ± 384.4*  |
| WHR (mm/day)             | 2.7 ± 1.3     | 0.5 ± 2.1†      |
| **At presentation**      |               |                 |
| Wound duration (days)    | 61 ± 11       | 153 ± 49*       |
| Ulcer size (mm²)         | 316.9 ± 509.9 | 329.4 ± 478.4  |
| Pro–MMP-9 (µg/ml)        | 4.47 ± 2.75   | 8.19 ± 2.75†   |
| Active–MMP-9 (µg/ml)     | 1.18 ± 1.21   | 2.90 ± 1.64*   |
| TIMP-1 (pg/ml)           | 732.5 ± 270.0 | 531.2 ± 377.6* |
| Pro–MMP-9-to–TIMP-1 ratio| 7.2 ± 5.24    | 18.88 ± 6.87*  |
| Active–MMP-9-to–TIMP-1 ratio| 2.03 ± 2.47 | 6.01 ± 1.08*   |
| Pro–MMP-2 (µg/ml)        | 1.01 ± 1.00   | 1.46 ± 1.25    |
| TGF-β1 (pg/ml)           | 231.9 ± 141.9 | 142.4 ± 119.7† |
| **Subsample with neuropathic ulcers only** |           |                 |
| Patients                 | 23            | 25              |
| Antibiotic treatment     | 20 of 23      | 22 of 25        |
| **At presentation**      |               |                 |
| Pro–MMP-9 (µg/ml)        | 3.92 ± 1.24   | 9.14 ± 3.84    |
| Active–MMP-9 (µg/ml)     | 1.20 ± 0.94   | 2.55 ± 1.24    |
| Pro–MMP-9-to–TIMP-1 ratio| 10.17 ± 8.24  | 34.81 ± 12.87* |
| Active–MMP-9-to–TIMP-1 ratio| 3.33 ± 1.47 | 8.11 ± 3.08*   |
| TIMP-1 (pg/ml)           | 683.59 ± 230.0| 523.68 ± 150.0†|
| TGF-β1 (pg/ml)           | 192 ± 90.6    | 112.4 ± 59.7†  |

Data are means ± SD or n. *P < 0.05 different from group with ulcers healed within 12 weeks. †P < 0.01 different from group with ulcers healed within 12 weeks.

ulcers (there were not sufficient numbers for comparison in stages A and D) and remained so if only the 48 neuropathic ulcers were analyzed (Table 1). The pro- and active–MMP-2 concentrations were also slightly higher (1.5-fold) in the unhealed group, but only the ratios of pro- and active–MMP-2 to TIMP-1 (threefold) attained significance. Wound fluid obtained after 4 weeks of treatment also showed the same pattern of higher pro–MMP-9 (mean ± SD unhealed concentration 7.28 ± 4.62 vs. healed concentration 4.73 ± 4.47 µg/ml), higher active–MMP-9 (1.87 ± 3.19 vs. 1.32 ± 1.97 µg/ml), and a higher pro–MMP-9-to–TIMP-1 ratio (23.17 ± 3.81 vs. 8.36 ± 10.95). The protein concentration of the wound fluid was 10.4 ± 5.5 mg/ml in the unhealed and 13.1 ± 6.3 mg/ml in the healed group.

Wound fluid pro–MMP-9, active–MMP-9, and TIMP-1 at presentation accounted for 32% of the variance in healing rate. Duration of diabetes, age, initial wound size, and TGF-β1 were not statistically significant determinants. Measurement of pro–MMP-9 with addition of cutoffs for TIMP-1 at >480 pg/ml and TGF-β1 at >115 pg/ml (respective median values for healed wounds) was the best predictor of wound healing (area under the curve 0.94; P < 0.00001). The sensitivity and specificity were 87 and 91%, respectively, and predicted outcome in 94% of cases.

**CONCLUSIONS**—The results of our study have shown for the first time that high wound fluid concentrations of MMP-9 and high MMP-9-to–TIMP-1 ratios predict poor wound healing in diabetic foot ulcers. The mechanism of increased MMP-9 is uncertain. However, it is likely to be related to increased inflammation because MMP-9 is expressed mainly by neutrophils and macrophages, both cell types important to the inflammatory response (13). This pattern of increased MMP-9 in poorly healing ulcers was observed in varying types of diabetic foot ulcers, suggesting that it is more strongly linked with the healing process rather than with underlying etiology. We have previously shown that high wound fluid bacterial count, even in the absence of overt infection, is also predictive of poor wound healing (10). It is possible that high bacterial count and high MMPs are mechanistically linked in this regard. As such, the results could be affected by antibiotic therapy, which most of our patients were given, but we have not systematically examined this aspect. It is unlikely that the pattern we have observed is due to increased exudates in nonhealing wounds. First, the protein concentration of the nonhealed ulcer group was actually lower than that of the healed group. Second, a simple change in the amount of exudates should not affect the various components such as MMPs and TIMPs differently.

Our study using wound fluid collected by an easy noninvasive technique is an important step to facilitate investigations in this area of study. One of the frustrations for clinicians treating diabetic foot ulcers is that there is not a simple test that can integrate various risk factors to allow prediction of achieving wound healing. Although our results need confirmation, it would be very useful if an index calculated from the measurements of MMPs, TIMP-1, and TGF-β1 at the initial presentation could assist in prognosis.

**Acknowledgments**—This study was supported by grants from the Diabetes Australia Research Trust and the Medical Foundation of The University of Sydney.

No potential conflicts of interest relevant to this article were reported.

**References**

1. Boulton AJ, Kirsner RS, Vileikyte L: Neuropathic diabetic foot ulcers. *N Engl J Med* 351:48–55, 2004
2. Lobmann R, Ambrosch A, Schulz G, Waldmann K, Schiweck S, Lehner H: Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. *Diabetologia* 45:1011–1016, 2002
3. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K: Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. *Plast Reconstr Surg* 105:638–647, 2000
4. Madlener M, Parks WC, Werner S: Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. *Exp Cell Res* 242:201–210, 1998

5. Lobmann R, Zemlin C, Motzkau M, Reischke K, Lehner H: Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. *J Diabetes Complications* 20:329–335, 2006

6. Vaalamo M, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J, Saarialho-Kere UK: Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. *Br J Dermatol* 135:52–59, 1996

7. Medina A, Scott PG, Ghahary A, Tredget EE: Pathophysiology of chronic nonhealing wounds. *J Burn Care Rehabil* 26:306–319, 2005

8. Parks WC: Matrix metalloproteinases in repair. *Wound Repair Regen* 7:423–432, 1999

9. Watelet JB, Claeyss C, Van Cauwenberge P, Bachert C: Predictive and monitoring value of matrix metalloproteinase-9 for healing quality after sinus surgery. *Wound Repair Regen* 12:412–418, 2004

10. Xu L, McLennan SV, Lo L, Natfaji A, Bolton T, Liu Y, Twigg SM, Yue DK: Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. *Diabetes Care* 30:378–380, 2007

11. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB, Boulton AJ: The effects of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. *Diabet Med* 18:133–138, 2001

12. Min D, Lyons JG, Jia J, Lo L, McLennan SV: 2-Methoxy-2,4-diphenyl-3(2H)-furanone-labeled gelatin zymography and reverse zymography: a rapid real-time method for quantification of matrix metalloproteinases-2 and -9 and tissue inhibitors of metalloproteinases. *Electrophoresis* 27:357–364, 2006

13. Falanga V: Wound healing and its impairment in the diabetic foot. *Lancet* 366:1736–1743, 2005